Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 10/20 | 0.73 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.68 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.68 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.63 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14079716 | 1.00 | NR1I2 (0.73) | NR1I2KCNH2CYP3A4SCN5ACYP2C9 | |
| SCHEMBL2346984 | 0.93 | KCNH2 (0.67) | NR1I2KCNH2CYP3A4SCN5ACYP2C9 | |
| SCHEMBL2344132 | 0.93 | NR1I2 (0.77) | NR1I2KCNH2CYP3A4SCN5ACYP2C9 | |
| SCHEMBL2340957 | 0.93 | NR1I2 (0.77) | NR1I2KCNH2CYP3A4SCN5ACYP2C9 | |
| SCHEMBL13868632 | 0.93 | NR1I2 (0.79) | NR1I2KCNH2CYP3A4SCN5ACYP2C9 | |
| SCHEMBL2350356 | 0.92 | NR1I2 (0.76) | NR1I2KCNH2CYP3A4SCN5ACYP2C9 | |
| SCHEMBL2344027 | 0.91 | NR1I2 (0.81) | NR1I2KCNH2CYP3A4SCN5ACYP2C9 | |
| SCHEMBL2346421 | 0.90 | NR1I2 (0.73) | NR1I2KCNH2CYP3A4SCN5ACYP2C9 | |
| SCHEMBL14391660 | 0.89 | NR1I2 (0.77) | NR1I2KCNH2CYP3A4SCN5ACYP2C9 | |
| SCHEMBL12034522 | 0.89 | NR1I2 (0.83) | NR1I2KCNH2CYP3A4SCN5ACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7521444-B2 | Compounds for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-04-21 | — | — | US | disclosed |
| US-7521444-B2 | Compounds for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-04-21 | — | — | US | disclosed |
| US-20080226590-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2008-09-18 | — | — | US | disclosed |
| US-20080226590-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2008-09-18 | — | — | US | disclosed |
| WO-2008112841-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-09-18 | — | — | WO | disclosed |
| WO-2007136982-A1 | CYCLOPROPYL FUSED INDOLOBENZAZEPINE HCV NS5B INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080226590-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, HCCS, SLC10A1 | NR1I2 189/4885KCNH2 3808/4885CYP3A4 214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.